Monitoring Atrial Fibrillation In Clinical Research: The Case For Continuous Wearable Assessment

By Michael Pettinati, PhD

Atrial fibrillation (AFib) is the most common cardiac arrhythmia worldwide, yet it remains notoriously difficult to detect and measure. Because AFib often comes and goes unpredictably and can occur without symptoms, standard tools like periodic ECGs frequently miss it. This challenge is especially pronounced in populations with heart failure, coronary artery disease, obesity, chronic kidney disease, and those recovering from cardiac surgery, where AFib is both more prevalent and more consequential.

Continuous, wearable monitoring offers a path forward. Photoplethysmography (PPG)-based sensors can passively track pulse irregularities suggestive of AFib around the clock, while accelerometry captures objective activity and functional data that complement rhythm findings. With robust validation data and a recent FDA qualification that establishes PPG-derived AFib burden as an accepted trial endpoint, these tools are reshaping how sponsors approach detection, monitoring, and endpoint design in cardiovascular research. For clinical development teams designing studies in AFib or related comorbid conditions, this piece offers a framework for evaluating how continuous, multimodal monitoring can close the detection gap, reduce patient burden, and strengthen the reliability of trial endpoints.